Incidence Trends, Outcomes, and Factors Associated with Mortality in Multisystem Inflammatory Syndrome in Children: A Nationwide Study in Thailand during 2021-2023.
{"title":"Incidence Trends, Outcomes, and Factors Associated with Mortality in Multisystem Inflammatory Syndrome in Children: A Nationwide Study in Thailand during 2021-2023.","authors":"Sirapoom Niamsanit, Phanthila Sitthikarnkha, Leelawadee Techasatian, Suchaorn Saengnipanthkul, Pope Kosalaraksa, Kaewjai Thepsuthammarat, Rattapon Uppala","doi":"10.1016/j.ijid.2026.108766","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Multisystem inflammatory syndrome in children (MIS-C) is a severe post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inflammatory condition. This study described MIS-C epidemiology and outcomes in Thailand during 2021-2023 and identified predictors of in-hospital death.</p><p><strong>Methods: </strong>A nationwide retrospective cohort study used Thai National Health Security Office (NHSO) inpatient data. Children aged 1 month to <18 years with MIS-C (ICD-10-TM codes U10 and U10.9) were included. Severe manifestations, organ dysfunction, and procedures were identified using ICD-10-TM, and ICD-9-CM codes. Logistic regression was used to evaluate mortality predictors.</p><p><strong>Results: </strong>Among 634 MIS-C hospitalizations (59.2% male; median age 6 years), National incidence peaked at 3.2 per 100,000 in 2022. In-hospital mortality was 3.2% with regional heterogeneity. Severe cardiac manifestations occurred in 37.4% and severe respiratory manifestations in 12.0%. Malignancy (adjusted odds ratio [AOR] 17.13; 95% confidence interval [95% CI] 1.84-159.92) and disseminated intravascular coagulation (DIC) (AOR 14.16; 95% CI 2.10-95.37) independently predicted mortality.</p><p><strong>Conclusions: </strong>MIS-C burden peaked in 2022 with regional variation. Early risk stratification and timely critical care with advanced organ support remains essential to optimize survival.</p>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":" ","pages":"108766"},"PeriodicalIF":4.3000,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijid.2026.108766","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Multisystem inflammatory syndrome in children (MIS-C) is a severe post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inflammatory condition. This study described MIS-C epidemiology and outcomes in Thailand during 2021-2023 and identified predictors of in-hospital death.
Methods: A nationwide retrospective cohort study used Thai National Health Security Office (NHSO) inpatient data. Children aged 1 month to <18 years with MIS-C (ICD-10-TM codes U10 and U10.9) were included. Severe manifestations, organ dysfunction, and procedures were identified using ICD-10-TM, and ICD-9-CM codes. Logistic regression was used to evaluate mortality predictors.
Results: Among 634 MIS-C hospitalizations (59.2% male; median age 6 years), National incidence peaked at 3.2 per 100,000 in 2022. In-hospital mortality was 3.2% with regional heterogeneity. Severe cardiac manifestations occurred in 37.4% and severe respiratory manifestations in 12.0%. Malignancy (adjusted odds ratio [AOR] 17.13; 95% confidence interval [95% CI] 1.84-159.92) and disseminated intravascular coagulation (DIC) (AOR 14.16; 95% CI 2.10-95.37) independently predicted mortality.
Conclusions: MIS-C burden peaked in 2022 with regional variation. Early risk stratification and timely critical care with advanced organ support remains essential to optimize survival.
期刊介绍:
International Journal of Infectious Diseases (IJID)
Publisher: International Society for Infectious Diseases
Publication Frequency: Monthly
Type: Peer-reviewed, Open Access
Scope:
Publishes original clinical and laboratory-based research.
Reports clinical trials, reviews, and some case reports.
Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases.
Emphasizes diseases common in under-resourced countries.